查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2040911

反義和RNAi療法市場預測至2034年—按給藥途徑、適應症、技術、應用和地區分類的全球分析

Antisense & RNAi Therapeutics Market Forecasts to 2034 - Global Analysis By Route of Administration, Indication, Technology, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球反義和 RNAi 療法市場規模將達到 23.9 億美元，在預測期內以 13.0% 的複合年成長率成長，到 2034 年將達到 33.6 億美元。

反義療法利用單鏈DNA寡核苷酸選擇性地、序列特異性抑制基因表現。它用於治療肌萎縮側索硬化症（ALS）、亨廷頓舞蹈症和阿茲海默症。另一方面， RNA干擾（RNAi）療法由雙鏈RNA（dsRNA）誘導，在dsRNA的作用下，導致標靶單鏈RNA的mRNA序列特異性分解。 RNAi療法可用於治療多種疾病，包括病毒感染疾病、神經退化性疾病和某些癌症。

根據美國科學促進會 (AAAS) 於 2023 年 7 月發表的報導，馬薩諸塞大學陳曾熙醫學院和拉什大學醫學中心開發的一種反義療法已被發現有助於恢復從脆弱X染色體症候群患者細胞檢體中取出的 FMRP 蛋白的產生。

遺傳性疾病增加

遺傳性疾病是由個別DNA異常引起的，而針對這些疾病的傳統治療方案往往有限。反義療法和RNA干擾（RNAi）療法透過在分子層面上靶向這些疾病的潛在遺傳病因，提供了一種極具前景的治療方法。此外，隨著遺傳性疾病盛行率的不斷上升，針對反義療法和RNAi療法的臨床試驗和研究活動也呈現爆炸性成長。成功的臨床試驗和監管部門的核准進一步證實了這些治療方法的潛力，並推動了市場成長。

基於RNAi的藥物高成本

複雜的研發過程涉及先進技術和嚴格的監管要求，導致生產成本較高。這些成本通常反映在RNAi療法的價格上，限制了患者和醫療系統的可及性。提供價格合理的治療方案的挑戰可能會阻礙其廣泛應用，並抑制市場成長潛力。因此，市場成長將受到抑制。

新型藥物傳遞技術的快速普及和RNA療法的市場化

先進藥物傳遞技術的出現提高了反義寡核苷酸和RNA干擾（RNAi）療法的療效和標靶遞送能力，加速了其廣泛應用。此外，RNA治療方法獲得監管部門核准並成功進入市場，提振了投資者信心，並促進了研發投入。技術進步與監管里程碑的融合，為反義寡核苷酸和RNAi療法市場創造了有利環境。

免疫反應

當外源性RNA分子（例如用於反義療法或RNA干擾（RNAi）療法的RNA分子）被引入體內時，免疫系統可能會被活化。這可能觸發先天免疫反應，包括促發炎細胞激素的釋放和免疫細胞的活化。或者，身體的適應性免疫系統可能將外源性RNA識別為威脅，從而導致產生針對治療分子的抗體。

新冠疫情的影響

新冠疫情對反義和RNAi療法市場產生了複雜的影響。一方面，人們對mRNA疫苗研發的關注度提高，加速了RNA技術的普及。另一方面，臨床試驗、供應鏈和研究活動的中斷延緩了反義和RNAi療法的研發和商業化。儘管RNA技術的普及是一個積極的訊號，但該行業仍面臨著適應不斷變化的環境的挑戰，這凸顯了在後疫情時代實現永續成長所需的韌性和適應能力的重要性。

在預測期內，RNA反義領域預計將是規模最大的領域。

RNA反義領域預計將佔據最大的市場佔有率。這種創新療法旨在透過抑製或改變疾病相關蛋白的產生，從基因層面治療疾病。 RNA反義技術在多種應用領域展現出巨大潛力，包括治療遺傳性疾病、癌症和病毒感染疾病。憑藉其精準干預基因表現表現的能力，RNA反義技術已成為廣大市場中的關鍵領域，並正推動著針對多種疾病的標靶和個人化治療方案的開發。

預計在預測期內，癌症治療領域將呈現最高的複合年成長率。

預計在預測期內，癌症領域將迎來顯著成長。反義和RNA干擾（RNAi）療法旨在選擇性地靶向和調控癌症相關基因的表達，從而抑制腫瘤進展或促進癌細胞死亡。該領域涵蓋多種療法，包括根據個體基因譜量身定做的個人化RNA療法。由於其靶向性和精準性，這些治療方法有望透過作用於特定的生物通路，在提高療效的同時最大限度地減少副作用，從而革新腫瘤治療領域。

市佔率最大的地區：

預計亞太地區將在預測期內佔據最大的市場佔有率，這主要得益於研發投入的增加、慢性病盛行率的上升以及有利的法規環境。中國、日本和印度等領先國家處於領先地位，致力於新型RNA治療方法的開發和商業化。此外，本地和全球生物技術公司之間的合作，以及人們對個人化醫療日益成長的認知，都在推動這一領域的發展。

複合年成長率最高的地區：

預計北美在預測期內將保持強勁成長。以美國主導的北美地區在製藥和生物技術研發領域投入大量資金，加速了新型RNA藥物的開發。有利的監管環境、相關人員之間的策略聯盟以及慢性病的高發生率均推動了市場擴張。此外，完善的醫療保健基礎設施、積極推動個人化醫療以及強大的市場參與者也是推動市場成長的重要因素。北美在反義RNA和RNAi治療方法研發領域處於領先地位，在全球市場中扮演著舉足輕重的角色。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章：執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球反義與RNAi療法市場：依給藥途徑分類

  • 皮下注射
  • 靜脈注射
  • 肺部輸送
  • 鞘內給藥
  • 腹腔注射
  • 其他給藥途徑

第6章 全球反義與RNAi治療市場：依適應症分類

  • 體染色體顯性遺傳疾病
  • 體染色體隱性遺傳疾病
  • 染色體異常
  • 其他改編

第7章 全球反義與RNAi療法市場：依技術分類

  • RNA反義
  • RNA干擾

第8章 全球反義與RNAi治療市場：依應用分類

  • 眼科疾病
  • 呼吸系統疾病
  • 心血管和代謝性疾病以及腎臟疾病
  • 癌症
  • 神經退化性疾病
  • 感染疾病
  • 遺傳性疾病
  • 皮膚病
  • 其他用途

第9章 全球反義與RNAi治療市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • Alnylam Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals（Akcea Therapeutics, Inc.）
  • Biogen Inc.
  • Sarepta Therapeutics, Inc.
  • Arbutus Biopharma
  • Silence Therapeutics
  • Isarna Therapeutics GmbH
  • Arrowhead Pharmaceuticals, Inc.
  • Gene Signal International SA
  • Benitec Biopharma Ltd
  • Olix Pharmaceuticals
  • GSK plc
  • Sanofi
  • Bio-Path Holdings Inc
  • Antisense Therapeutics Limited.
  • Quark Pharmaceuticals
  • Merck
  • Astellas Pharma Inc
  • Marina Biosciences
  • Dicerna Pharmaceuticals
Product Code: SMRC25123

According to Stratistics MRC, the Global Antisense & RNAi Therapeutics Market is accounted for $2.39 billion in 2026 and is expected to reach $3.36 billion by 2034 growing at a CAGR of 13.0% during the forecast period. Antisense therapy is the selective and sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. It is used to treat amyotrophic lateral sclerosis and Huntington's and Alzheimer's disease. On the other hand, RNA interference (RNAi) therapy is triggered by double-stranded RNA (dsRNA) and causes sequence-specific ribonucleic acid (mRNA) degradation of single-stranded target RNAs in response to dsRNA. RNAi has applications in treating a wide range of conditions, including viral infections, neurodegenerative diseases, and certain cancers.

According to the article published by the American Association for the Advancement of Science in July 2023, an antisense therapy developed by UMass Chan Medical School and RUSH University Medical Center is found useful in restoring production of the protein FMRP in cell specimens taken from individuals suffering from fragile X syndrome.

Market Dynamics:

Driver:

Rising incidence of genetic disorders

Genetic disorders result from abnormalities in an individual's DNA, and traditional treatment options for these conditions are often limited. Antisense and RNA interference (RNAi) therapies offer a promising approach by targeting the underlying genetic causes of these disorders at the molecular level. Furthermore, the increasing prevalence of genetic disorders has prompted a surge in clinical trials and research efforts focusing on antisense and RNAi therapies. Successful trials and regulatory approvals further validate the potential of these treatments, driving market growth.

Restraint:

High cost of RNAi based drugs

The complex development process, involving advanced technologies and stringent regulatory requirements, contributes to elevated production costs. These expenses are often reflected in the pricing of RNAi therapeutics, limiting accessibility for patients and healthcare systems. Affordability challenges can impede widespread adoption, hindering the market's growth potential. As a result, it will hamper market growth.

Opportunity:

Rapid adoption of novel drug delivery and launch of RNA therapeutics

The advent of advanced drug delivery technologies has enhanced the efficacy and targeted delivery of antisense and RNA interference (RNAi) therapeutics, fostering their widespread adoption. Furthermore, the regulatory approval and successful market entry of RNA-based treatments have bolstered investor confidence and fuelled research and development initiatives. This convergence of technological advancements and regulatory milestones has created a favourable environment, propelling the Antisense & RNAi Therapeutics Market.

Threat:

Immune responses

When exogenous RNA molecules, such as those used in antisense and RNA interference (RNAi) therapies, are introduced into the body, they may activate the immune system. This can trigger innate immune responses, including the release of pro-inflammatory cytokines and the activation of immune cells. Also, the body's adaptive immune system may recognize the foreign RNA as a threat, leading to the production of antibodies against the therapeutic molecules.

Covid-19 Impact

The COVID-19 pandemic has had a mixed impact on the antisense and RNAi therapeutics markets. On one hand, the focus on mRNA vaccine development has accelerated RNA-based technology acceptance. However, disruptions in clinical trials, supply chains, and research activities have caused delays in the development and commercialization of anti-sense and RNAi therapies. While increased recognition of RNA technologies is a positive outcome, the industry faces challenges in adapting to the changing landscape, emphasising the importance of resilience and adaptability for continued growth in a post-pandemic era.

The RNA antisense segment is expected to be the largest during the forecast period

The RNA antisense segment is estimated to hold the largest share. This innovative therapeutic approach aims to treat diseases at the genetic level by inhibiting or modifying the production of disease-related proteins. RNA antisense technology holds promise for various applications, including treating genetic disorders, cancers, and viral infections. With its ability to precisely intervene in gene expression, RNA antisense represents a pivotal segment within the broader market, contributing to the development of targeted and personalised therapeutic solutions for a range of medical conditions.

The cancer segment is expected to have the highest CAGR during the forecast period

The cancer segment is anticipated to have lucrative growth during the forecast period. Antisense and RNA interference (RNAi) therapies are designed to selectively target and modulate the expression of genes associated with cancer, inhibiting tumour progression or promoting cancer cell death. This segment encompasses a diverse range of approaches, including personalised RNA treatments tailored to individual genetic profiles. Because of their targeted and precise nature, these treatments have the potential to alter oncology by tackling certain biological pathways and improving therapeutic efficacy while minimising side effects.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to increased investment in research and development, the rising prevalence of chronic diseases, and a supportive regulatory environment. Key countries such as China, Japan, and India are at the forefront, with a focus on developing and commercialising novel RNA-based therapies. Furthermore, collaborations between local and global biotech firms, along with a growing awareness of personalised medicine, drive advancements.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. The region, lead by the US, has made significant expenditures in pharmaceutical and biotechnology research, which has stimulated the development of novel RNA-based medicines. Favourable regulatory landscapes, strategic collaborations between industry stakeholders and a high prevalence of chronic diseases contribute to market expansion. It also has a well-established healthcare infrastructure, a proactive approach to personalised medicine, and prominent market players. North America is at the forefront of the development of antisense and RNAi treatments, making it a dynamic and significant player in the worldwide market.

Key players in the market

Some of the key players in the Antisense & RNAi Therapeutics Market include Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals (Akcea Therapeutics, Inc.), Biogen Inc, Sarepta Therapeutics, Inc, Arbutus Biopharma, Silence Therapeutics, Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals, Inc, Gene Signal International SA, Benitec Biopharma Ltd, Olix Pharmaceuticals, GSK plc, Sanofi, Bio-Path Holdings Inc, Antisense Therapeutics Limited., Quark Pharmaceuticals, Merck, Astellas Pharma Inc, Marina Biosciences and Dicerna Pharmaceuticals.

Key Developments:

In July 2023, Alnylam Pharmaceuticals, Inc. partnered with Roche; to develop and market, zilebesiran, investigational ribonucleic acid interference (RNAi) therapeutic to treat hypertension

In March 2023, OliX Pharmaceuticals, Inc. dosed the first patient in a Phase 1 clinical trial of an investigational RNAi therapeutic designed to treat age-related macular degeneration (AMD)

Routes of Administration Covered:

  • Subcutaneous Route
  • Intravenous Route
  • Pulmonary Delivery
  • Intrathecal Route
  • Intraperitoneal Injection
  • Other Routes of Administration

Indications Covered:

  • Autosomal Dominant Disease
  • Autosomal Recessive Disease
  • Chromosomal Disease
  • Other Indications

Technologies Covered:

  • RNA Antisense
  • RNA Interference

Applications Covered:

  • Ocular Disorders
  • Respiratory Disorders
  • Cardio metabolic & Renal Disorders
  • Cancer
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Genetic Disorders
  • Skin Diseases
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Antisense & RNAi Therapeutics Market, By Route of Administration

  • 5.1 Introduction
  • 5.2 Subcutaneous Route
  • 5.3 Intravenous Route
  • 5.4 Pulmonary Delivery
  • 5.5 Intrathecal Route
  • 5.6 Intraperitoneal Injection
  • 5.7 Other Routes of Administration

6 Global Antisense & RNAi Therapeutics Market, By Indication

  • 6.1 Introduction
  • 6.2 Autosomal Dominant Disease
  • 6.3 Autosomal Recessive Disease
  • 6.4 Chromosomal Disease
  • 6.5 Other Indications

7 Global Antisense & RNAi Therapeutics Market, By Technology

  • 7.1 Introduction
  • 7.2 RNA Antisense
  • 7.3 RNA Interference

8 Global Antisense & RNAi Therapeutics Market, By Application

  • 8.1 Introduction
  • 8.2 Ocular Disorders
  • 8.3 Respiratory Disorders
  • 8.4 Cardio metabolic & Renal Disorders
  • 8.5 Cancer
  • 8.6 Neurodegenerative Disorders
  • 8.7 Infectious Diseases
  • 8.8 Genetic Disorders
  • 8.9 Skin Diseases
  • 8.10 Other Applications

9 Global Antisense & RNAi Therapeutics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Alnylam Pharmaceuticals, Inc.
  • 11.2 Ionis Pharmaceuticals (Akcea Therapeutics, Inc.)
  • 11.3 Biogen Inc.
  • 11.4 Sarepta Therapeutics, Inc.
  • 11.5 Arbutus Biopharma
  • 11.6 Silence Therapeutics
  • 11.7 Isarna Therapeutics GmbH
  • 11.8 Arrowhead Pharmaceuticals, Inc.
  • 11.9 Gene Signal International SA
  • 11.10 Benitec Biopharma Ltd
  • 11.11 Olix Pharmaceuticals
  • 11.12 GSK plc
  • 11.13 Sanofi
  • 11.14 Bio-Path Holdings Inc
  • 11.15 Antisense Therapeutics Limited.
  • 11.16 Quark Pharmaceuticals
  • 11.17 Merck
  • 11.18 Astellas Pharma Inc
  • 11.19 Marina Biosciences
  • 11.20 Dicerna Pharmaceuticals

List of Tables

  • Table 1 Global Antisense & RNAi Therapeutics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 3 Global Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2023-2034) ($MN)
  • Table 4 Global Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2023-2034) ($MN)
  • Table 5 Global Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2023-2034) ($MN)
  • Table 6 Global Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2023-2034) ($MN)
  • Table 7 Global Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2023-2034) ($MN)
  • Table 8 Global Antisense & RNAi Therapeutics Market Outlook, By Other Routes of Administration (2023-2034) ($MN)
  • Table 9 Global Antisense & RNAi Therapeutics Market Outlook, By Indication (2023-2034) ($MN)
  • Table 10 Global Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2023-2034) ($MN)
  • Table 11 Global Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2023-2034) ($MN)
  • Table 12 Global Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2023-2034) ($MN)
  • Table 13 Global Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 14 Global Antisense & RNAi Therapeutics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 15 Global Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2023-2034) ($MN)
  • Table 16 Global Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2023-2034) ($MN)
  • Table 17 Global Antisense & RNAi Therapeutics Market Outlook, By Application (2023-2034) ($MN)
  • Table 18 Global Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2023-2034) ($MN)
  • Table 19 Global Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2023-2034) ($MN)
  • Table 20 Global Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2023-2034) ($MN)
  • Table 21 Global Antisense & RNAi Therapeutics Market Outlook, By Cancer (2023-2034) ($MN)
  • Table 22 Global Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2023-2034) ($MN)
  • Table 23 Global Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 24 Global Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2023-2034) ($MN)
  • Table 25 Global Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2023-2034) ($MN)
  • Table 26 Global Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 27 North America Antisense & RNAi Therapeutics Market Outlook, By Country (2023-2034) ($MN)
  • Table 28 North America Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 29 North America Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2023-2034) ($MN)
  • Table 30 North America Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2023-2034) ($MN)
  • Table 31 North America Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2023-2034) ($MN)
  • Table 32 North America Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2023-2034) ($MN)
  • Table 33 North America Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2023-2034) ($MN)
  • Table 34 North America Antisense & RNAi Therapeutics Market Outlook, By Other Routes of Administration (2023-2034) ($MN)
  • Table 35 North America Antisense & RNAi Therapeutics Market Outlook, By Indication (2023-2034) ($MN)
  • Table 36 North America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2023-2034) ($MN)
  • Table 37 North America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2023-2034) ($MN)
  • Table 38 North America Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2023-2034) ($MN)
  • Table 39 North America Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 40 North America Antisense & RNAi Therapeutics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 41 North America Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2023-2034) ($MN)
  • Table 42 North America Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2023-2034) ($MN)
  • Table 43 North America Antisense & RNAi Therapeutics Market Outlook, By Application (2023-2034) ($MN)
  • Table 44 North America Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2023-2034) ($MN)
  • Table 45 North America Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2023-2034) ($MN)
  • Table 46 North America Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2023-2034) ($MN)
  • Table 47 North America Antisense & RNAi Therapeutics Market Outlook, By Cancer (2023-2034) ($MN)
  • Table 48 North America Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2023-2034) ($MN)
  • Table 49 North America Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 50 North America Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2023-2034) ($MN)
  • Table 51 North America Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2023-2034) ($MN)
  • Table 52 North America Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 53 Europe Antisense & RNAi Therapeutics Market Outlook, By Country (2023-2034) ($MN)
  • Table 54 Europe Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 55 Europe Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2023-2034) ($MN)
  • Table 56 Europe Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2023-2034) ($MN)
  • Table 57 Europe Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2023-2034) ($MN)
  • Table 58 Europe Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2023-2034) ($MN)
  • Table 59 Europe Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2023-2034) ($MN)
  • Table 60 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Routes of Administration (2023-2034) ($MN)
  • Table 61 Europe Antisense & RNAi Therapeutics Market Outlook, By Indication (2023-2034) ($MN)
  • Table 62 Europe Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2023-2034) ($MN)
  • Table 63 Europe Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2023-2034) ($MN)
  • Table 64 Europe Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2023-2034) ($MN)
  • Table 65 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 66 Europe Antisense & RNAi Therapeutics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 67 Europe Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2023-2034) ($MN)
  • Table 68 Europe Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2023-2034) ($MN)
  • Table 69 Europe Antisense & RNAi Therapeutics Market Outlook, By Application (2023-2034) ($MN)
  • Table 70 Europe Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2023-2034) ($MN)
  • Table 71 Europe Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2023-2034) ($MN)
  • Table 72 Europe Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2023-2034) ($MN)
  • Table 73 Europe Antisense & RNAi Therapeutics Market Outlook, By Cancer (2023-2034) ($MN)
  • Table 74 Europe Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2023-2034) ($MN)
  • Table 75 Europe Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 76 Europe Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2023-2034) ($MN)
  • Table 77 Europe Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2023-2034) ($MN)
  • Table 78 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 79 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Country (2023-2034) ($MN)
  • Table 80 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 81 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2023-2034) ($MN)
  • Table 82 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2023-2034) ($MN)
  • Table 83 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2023-2034) ($MN)
  • Table 84 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2023-2034) ($MN)
  • Table 85 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2023-2034) ($MN)
  • Table 86 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Routes of Administration (2023-2034) ($MN)
  • Table 87 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Indication (2023-2034) ($MN)
  • Table 88 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2023-2034) ($MN)
  • Table 89 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2023-2034) ($MN)
  • Table 90 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2023-2034) ($MN)
  • Table 91 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 92 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 93 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2023-2034) ($MN)
  • Table 94 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2023-2034) ($MN)
  • Table 95 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Application (2023-2034) ($MN)
  • Table 96 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2023-2034) ($MN)
  • Table 97 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2023-2034) ($MN)
  • Table 98 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2023-2034) ($MN)
  • Table 99 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Cancer (2023-2034) ($MN)
  • Table 100 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2023-2034) ($MN)
  • Table 101 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 102 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2023-2034) ($MN)
  • Table 103 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2023-2034) ($MN)
  • Table 104 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 105 South America Antisense & RNAi Therapeutics Market Outlook, By Country (2023-2034) ($MN)
  • Table 106 South America Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 107 South America Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2023-2034) ($MN)
  • Table 108 South America Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2023-2034) ($MN)
  • Table 109 South America Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2023-2034) ($MN)
  • Table 110 South America Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2023-2034) ($MN)
  • Table 111 South America Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2023-2034) ($MN)
  • Table 112 South America Antisense & RNAi Therapeutics Market Outlook, By Other Routes of Administration (2023-2034) ($MN)
  • Table 113 South America Antisense & RNAi Therapeutics Market Outlook, By Indication (2023-2034) ($MN)
  • Table 114 South America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2023-2034) ($MN)
  • Table 115 South America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2023-2034) ($MN)
  • Table 116 South America Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2023-2034) ($MN)
  • Table 117 South America Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 118 South America Antisense & RNAi Therapeutics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 119 South America Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2023-2034) ($MN)
  • Table 120 South America Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2023-2034) ($MN)
  • Table 121 South America Antisense & RNAi Therapeutics Market Outlook, By Application (2023-2034) ($MN)
  • Table 122 South America Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2023-2034) ($MN)
  • Table 123 South America Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2023-2034) ($MN)
  • Table 124 South America Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2023-2034) ($MN)
  • Table 125 South America Antisense & RNAi Therapeutics Market Outlook, By Cancer (2023-2034) ($MN)
  • Table 126 South America Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2023-2034) ($MN)
  • Table 127 South America Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 128 South America Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2023-2034) ($MN)
  • Table 129 South America Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2023-2034) ($MN)
  • Table 130 South America Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 131 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Country (2023-2034) ($MN)
  • Table 132 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 133 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2023-2034) ($MN)
  • Table 134 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2023-2034) ($MN)
  • Table 135 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2023-2034) ($MN)
  • Table 136 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2023-2034) ($MN)
  • Table 137 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2023-2034) ($MN)
  • Table 138 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Routes of Administration (2023-2034) ($MN)
  • Table 139 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Indication (2023-2034) ($MN)
  • Table 140 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2023-2034) ($MN)
  • Table 141 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2023-2034) ($MN)
  • Table 142 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2023-2034) ($MN)
  • Table 143 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 144 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 145 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2023-2034) ($MN)
  • Table 146 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2023-2034) ($MN)
  • Table 147 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Application (2023-2034) ($MN)
  • Table 148 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2023-2034) ($MN)
  • Table 149 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2023-2034) ($MN)
  • Table 150 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2023-2034) ($MN)
  • Table 151 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Cancer (2023-2034) ($MN)
  • Table 152 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2023-2034) ($MN)
  • Table 153 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 154 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2023-2034) ($MN)
  • Table 155 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2023-2034) ($MN)
  • Table 156 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2023-2034) ($MN)